Niquitin Pre-Quit Clear (Nicotine)

Niquitin Pre-Quit Clear, a nicotine replacement therapy, is used in the management of nicotine dependence and smoking cessation.

• Smoking cessation: helps reduce cravings and withdrawal symptoms during the quitting process.
• Tobacco dependence: supports gradual reduction of nicotine intake for individuals who smoke regularly.
• Relapse prevention: provides a controlled nicotine supply to lower the risk of returning to smoking after an initial quit attempt.

• Nicotine delivered through the patch is absorbed through the skin into the systemic circulation, where it binds to nicotinic acetylcholine receptors in the brain. This stimulation partially mimics the effect of inhaled tobacco smoke, decreasing the intensity of withdrawal symptoms and cravings while allowing the user to taper nicotine exposure gradually.

The most frequently reported reactions to nicotine transdermal patches involve the skin at the application site, while rare systemic events may also occur.

Common Side Effects

• Skin irritation: redness, itching, or mild rash at the patch site.
• Burning sensation: localized warmth or tingling under the patch.
• Headache: mild to moderate headache during initial use.
• Nausea: occasional upset stomach or feeling of queasiness.
• Dizziness: light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Allergic reaction: hives, swelling, or severe rash beyond the application area.
• Severe skin dermatitis: blistering or intense inflammation at the site.
• Hypotension: unusually low blood pressure causing faintness.
• Tachycardia: rapid heart rate that persists.
• Chest pain: unexplained discomfort in the chest region.
• Syncope: sudden loss of consciousness.

Before using Niquitin Pre-Quit Clear, consider the following safety measures.

• Cardiovascular assessment: evaluate recent heart attack or unstable angina before initiating therapy.
• Blood pressure monitoring: avoid use in uncontrolled hypertension.
• Non‑smoker use: not intended for individuals who do not use tobacco products.
• Concomitant nicotine sources: do not combine with other nicotine replacement products.
• Pediatric safety: keep patches out of reach of children to prevent accidental exposure.
• Store at room temperature: keep in the original packaging, protect from moisture and direct heat.

Nicotine may interact with several medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use can increase the risk of hypertensive crisis.
• Certain antihypertensive agents (e.g., clonidine): nicotine may diminish their blood‑pressure‑lowering effect.
• Bupropion: combined use may raise the likelihood of seizures.

Moderate Interactions (Monitor Closely)

• CYP1A2 substrates (theophylline, caffeine): nicotine can induce metabolism, reducing their efficacy.
• Warfarin: nicotine may alter INR levels, requiring closer monitoring.
• Insulin or oral hypoglycemics: nicotine can affect glucose control, necessitating dose adjustments.